Immunocore Holdings plc - ADR
IMCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.78B
Close$
$-21.06
160.2% downside
Current Fair Value
160.2% downsideOvervalued by 160.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.78 Billion |
|---|---|
| Enterprise Value | $1.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.73 |
| Outstanding Shares | 50,754,763 |
Return
| Return on Equity | -4.78% |
|---|---|
| Return on Assets | -1.76% |
| Return on Invested Capital | -2.93% |
Valuation & Multiples
| P/E Ratio | -93.38 |
|---|---|
| PEG | -59.01 |
| Price to Sales | 5.0 |
| Price to Book Ratio | 5.0 |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | -56.11 |
| Enterprise Value to Net Income | -73 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$146.25 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$146.74 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 864.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.54%▼ 103.53% |
|---|---|
| Total Invested | $8.64M▼ 99.45% |
| Investors Holding | 12▼ 141.00% |
ESG Score
No data
About Immunocore Holdings plc
2,020 employeesImmunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of disea...